Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -16M | -22M | -12M | -4M |
| EBITDA | -12M | -15M | 0 | 0 | 4K |
| Net Income | -12M | -15M | -21M | -12M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0111
+0.00% today
1Y Change
-96.02%
Window
Jun 23, 2025 → Jun 19, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Virpax Pharmaceuticals, Inc. (VRPX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 96.0% across the available one-year price window (Jun 23, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -446.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -446.7%, free cash flow -169509.2% with operating margin 0.0% and ROIC 1322.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VRPX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRPX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRPX Max Drawdown
-99.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRPX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.5M
+63.1% YoY
Free Cash Flow
-$1.4M
+90.5% YoY
Revenue Growth
+0.0%
EPS Growth
-446.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12M | -16M | -22M | -12M | -4M |
| EBITDA | -12M | -15M | 0 | 0 | 4K |
| Net Income | -12M | -15M | -21M | -12M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 9M | 19M | 37M | 55K |
| Total Assets | 2M | 10M | 20M | 40M | 465K |
| Total Liabilities | 2M | 8M | 3M | 2M | 5M |
| Shareholder Equity | -914K | 2M | 17M | 37M | -4M |
| Total Debt | 0 | 0 | 0 | 0 | 2M |
| Net Debt | -2M | -9M | -19M | -37M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+90.5% YoY
Capital Expenditures
0
Free Cash Flow
1M
+90.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-2364.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.